Cargando…

The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors

The mechanisms of chemotherapy resistance in triple negative breast cancer remain unclear, and so, new molecules which might mediate this resistance could optimize treatment response. Here we analyzed the involvement of the miRNA-449 family in the response to doxorubicin. The cell viability, cell-cy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tormo, Eduardo, Ballester, Sandra, Adam-Artigues, Anna, Burgués, Octavio, Alonso, Elisa, Bermejo, Begoña, Menéndez, Silvia, Zazo, Sandra, Madoz-Gúrpide, Juan, Rovira, Ana, Albanell, Joan, Rojo, Federico, Lluch, Ana, Eroles, Pilar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441107/ https://www.ncbi.nlm.nih.gov/pubmed/30926829 http://dx.doi.org/10.1038/s41598-019-41472-y

Ejemplares similares

High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer
por: Torres-Ruiz, Sandra, et al.
Publicado: (2023)

miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer
por: Cabello, Paula, et al.
Publicado: (2023)

The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene
por: Tormo, Eduardo, et al.
Publicado: (2017)

PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects
por: Rincón, Raúl, et al.
Publicado: (2015)

miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies
por: Garrido‐Cano, Iris, et al.
Publicado: (2022)

Role of SALL4 in HER2+ Breast Cancer Progression: Regulating PI3K/AKT Pathway
por: Pattanayak, Birlipta, et al.
Publicado: (2022)

MicroRNA-33b Suppresses Epithelial–Mesenchymal Transition Repressing the MYC–EZH2 Pathway in HER2+ Breast Carcinoma
por: Pattanayak, Birlipta, et al.
Publicado: (2020)

The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models
por: Sanz-Álvarez, Marta, et al.
Publicado: (2021)

CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer
por: Luque, Melani, et al.
Publicado: (2022)

Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer
por: Luque, Melani, et al.
Publicado: (2021)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
por: Adam-Artigues, Anna, et al.
Publicado: (2022)

Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma
por: Rojo, Federico, et al.
Publicado: (2016)

Expression of Phosphorylated BRD4 Is Markedly Associated with the Activation Status of the PP2A Pathway and Shows a Strong Prognostic Value in Triple Negative Breast Cancer Patients
por: Sanz-Álvarez, Marta, et al.
Publicado: (2021)

HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women
por: Oltra, Sara S., et al.
Publicado: (2020)

The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer
por: González-Alonso, Paula, et al.
Publicado: (2020)

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
por: Pineda, Begoña, et al.
Publicado: (2019)

Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-κB target genes in human breast cancer
por: Dalmases, Alba, et al.
Publicado: (2013)

Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies
por: Tapia, Marta, et al.
Publicado: (2023)

Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer
por: Chamizo, Cristina, et al.
Publicado: (2015)

The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast Cancer
por: Cabello, Paula, et al.
Publicado: (2016)

Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer
por: Adam-Artigues, Anna, et al.
Publicado: (2021)

Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer
por: Madoz-Gúrpide, Juan, et al.
Publicado: (2015)

Clinical Relevance of +936 C>T VEGFA and c.233C>T bFGF Polymorphisms in Chronic Lymphocytic Leukemia
por: Ballester, Sandra, et al.
Publicado: (2020)

MicroRNAs as a clue to overcome breast cancer treatment resistance
por: Garrido-Cano, Iris, et al.
Publicado: (2021)

Low MicroRNA-19b Expression Shows a Promising Clinical Impact in Locally Advanced Rectal Cancer
por: Rubio, Jaime, et al.
Publicado: (2021)

Validation of microRNA-199b as A Promising Predictor of Outcome and Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer Patients
por: Cristóbal, Ion, et al.
Publicado: (2021)

MicroRNA-19b Plays a Key Role in 5-Fluorouracil Resistance and Predicts Tumor Progression in Locally Advanced Rectal Cancer Patients
por: Santos, Andrea, et al.
Publicado: (2022)

Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy
por: Garrido-Cano, Iris, et al.
Publicado: (2023)

Identification of Candidate Polymorphisms on Stress Oxidative and DNA Damage Repair Genes Related with Clinical Outcome in Breast Cancer Patients
por: Rodrigues, Patricia, et al.
Publicado: (2012)

Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective
por: Hernando, Cristina, et al.
Publicado: (2021)

Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer
por: Adam-Artigues, A., et al.
Publicado: (2021)

Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer
por: Luque, Melani, et al.
Publicado: (2022)

Breast Cancer in Very Young Patients in a Spanish Cohort: Age as an Independent Bad Prognostic Indicator
por: Martínez, María Teresa, et al.
Publicado: (2019)

Deregulation of SET is Associated with Tumor Progression and Predicts Adverse Outcome in Patients with Early-Stage Colorectal Cancer
por: Cristóbal, Ion, et al.
Publicado: (2019)

MicroRNA-199b Deregulation Shows a Strong SET-Independent Prognostic Value in Early-Stage Colorectal Cancer
por: Cristóbal, Ion, et al.
Publicado: (2020)

Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma
por: González-Alonso, Paula, et al.
Publicado: (2015)

Potential therapeutic value of miR‐425‐5p in metastatic colorectal cancer
por: Cristóbal, Ion, et al.
Publicado: (2016)

Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer
por: Cristóbal, I, et al.
Publicado: (2014)

Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer
por: Garrido-Cano, Iris, et al.
Publicado: (2020)

MicroRNA-199b Downregulation Confers Resistance to 5-Fluorouracil Treatment and Predicts Poor Outcome and Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients
por: Cristóbal, Ion, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cnjs1qae1hhlitvjg6182igt72